首页> Clinical chemistry> Multicenter Evaluation of Circulating Plasma MicroRNA Extraction Technologies for the Development of Clinically Feasible Reverse Transcription Quantitative PCR and Next-Generation Sequencing Analytical Work Flows.

Multicenter Evaluation of Circulating Plasma MicroRNA Extraction Technologies for the Development of Clinically Feasible Reverse Transcription Quantitative PCR and Next-Generation Sequencing Analytical Work Flows.

导出原文传递

翻译打印收藏纠错

第一作者： Vera,Kloten

第一单位： Bayer AG, Pharmaceutical Division, Biomarker Research, Wuppertal, Germany.

作者： Vera,Kloten ^[1] ; Martin H D,Neumann ^[2] ; Francesca,Di Pasquale ^[2] ; Markus,Sprenger-Haussels ^[2] ; Jonathan M,Shaffer ^[3] ; Martin,Schlumpberger ^[2] ; Andrei,Herdean ^[4] ; Fay,Betsou ^[5] ; Wim,Ammerlaan ^[5] ; Taija,Af Hällström ^[6] ; Elina,Serkkola ^[7] ; Tarja,Forsman ^[7] ; Evi,Lianidou ^[8] ; Robert,Sjöback ^[4] ; Mikael,Kubista ^[9] ; Sebastian,Bender ^[10] ; Rita,Lampignano ^[1] ; Thomas,Krahn ^[1] ; Thomas,Schlange ^[11] ; CANCER-ID consortium

作者单位： Bayer AG, Pharmaceutical Division, Biomarker Research, Wuppertal, Germany. ^[1] QIAGEN GmbH, Hilden, Germany. ^[2] QIAGEN, Frederick, MD. ^[3] TATAA Biocenter AB, Gothenburg, Sweden. ^[4] Integrated BioBank of Luxembourg, Dudelange, Luxembourg. ^[5] AstraZeneca, Espoo, Finland.;Institute for Molecular Medicine Finland, University of Helsinki, Helsinki, Finland.;Orion Pharma, Orion Corporation, Espoo, Finland. ^[6] Orion Pharma, Orion Corporation, Espoo, Finland. ^[7] University of Athens, Athens, Greece. ^[8] TATAA Biocenter AB, Gothenburg, Sweden.;Institute of Biotechnology CAS, v. v. i., Vestec, Czech Republic. ^[9] Bayer AG, Pharmaceutical Division, Translational Assay Technology, Berlin, Germany. ^[10] Bayer AG, Pharmaceutical Division, Biomarker Research, Wuppertal, Germany; thomas.schlange@bayer.com. ^[11]